ME Therapeutics Holdings, Inc. · NEO:METX

ME Therapeutics Holdings, Inc. financial statements

ME Therapeutics Holdings, Inc.'s income statement, balance sheet and cash flow, annual and quarterly, each figure dated and linked to the filing it was read from.

Financials

Annual, in CAD

Income statement

LineFY2025FY2024FY2023FY2022
Revenue0000
Research and development412.1K312.0K27.1K54.7K
Selling, general and administrative780.1K1.06M950.2K97.3K
Operating income-1.22M-1.37M-6.55M-162.8K
Depreciation and amortization83.3K405060
EBITDA-1.13M-1.37M-6.55M-162.7K
Interest expense12.7K07.46K10.8K
Income before tax-1.19M-1.29M-6.52M-145.8K
Net income-1.19M-1.29M-6.52M-145.8K
Earnings per share, basic-0.04-0.05-0.28-0.01

Balance sheet

LineFY2025FY2024FY2023FY2022
Cash and equivalents1.35M1.50M647.1K77.4K
Short-term investments57.5K0
Current assets1.50M1.54M671.7K102.2K
Property, plant and equipment160200250
Total assets1.76M1.54M671.9K102.5K
Accounts payable155.2K46.1K106.7K34.2K
Current liabilities245.4K62.9K148.5K173.9K
Long-term debt060.0K
Total liabilities256.3K62.9K148.5K233.9K
Shareholders' equity1.50M1.48M523.4K-131.5K
Shares outstanding29.6M25.2M23.6M23.6M

Cash flow

LineFY2025FY2024FY2023FY2022
Cash from operations-862.3K-657.9K-303.2K-135.7K
Capital spending-216.2K000
Free cash flow-1.08M-657.9K-303.2K-135.7K
Cash from investing0757.4K
Cash from financing995.5K1.51M115.5K140.0K
Share buybacks1.55M0
Change in cash-151.3K849.6K569.8K4.32K